ClinicalTrials.gg
CompletedNCT00303602Updated Jun 10, 2009Results posted

Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)

A Phase 4 interventional study of Sublingual orally disintegrating olanzapine (SODO) and Oral olanzapine in Schizophrenia, Schizoaffective Disorder and Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 21 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2009-06-10.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
36th of 94
149 · median 114
Started
2006
with 8 others
Phase 4
46 of 97
1 open now
Registered
37th of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 36th largest by enrollment of the 94 interventional ones that give a count, is one of 9 that started in 2006, is one of 46 in phase 4, and was the 37th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already gaining weight on olanzapine.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years old
  • Have gained weight while taking olanzapine
  • Be able to visit the doctor's office seven times over 4 months (17 weeks)

Exclusion criteria

Exclusion Criteria (Patients must NOT):

  • Have started a weight loss program within the last 8 weeks
  • Have an illness that might affect patient's weight during the study
  • Have an allergy to phenylalanine, mannitol or saccharine
  • Be taking any medication (except for olanzapine) that might affect patient's weight
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    A

    Sublingual orally disintegrating olanzapine (SODO)

    Drug: Sublingual orally disintegrating olanzapine (SODO)

  • Active comparator
    B

    Oral olanzapine

    Drug: Oral olanzapine

Interventions

  • 5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.

    Also known as: LY170053, Zydis

  • 5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.

    Also known as: LY170053, Zyprexa

06

What researchers measure

Primary outcomes

  1. Time Course of Change From Baseline in Body Mass Index (BMI)

    Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.

    Time frame: Visit 2 (Baseline) to Visit 7 (16 Weeks)

Secondary outcomes

  1. Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)

    Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of change from baseline to endpoint. Change = Endpoint (Week 16) minus Baseline (Week 0)

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  2. Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers

    Body mass index is an estimate of body fat based on body weight divided by height squared. Comparisons of change from baseline to endpoint between participants who completed their treatment. Change = Endpoint value minus Baseline value.

    Time frame: Visit 2 (Baseline) and Visit 7 (16 Weeks)

  3. Mean Change From Baseline to 16 Week Endpoint in Weight

    Weight of undressed patient (undergarments allowed), measured preferably at the same time each day.

    Time frame: Visit 2 (Baseline) and Visit 7 (16 Weeks)

  4. Mean Change From Baseline to 16 Week Endpoint in Waist Circumference

    Waist circumference is measured on a bare abodomen just above the hip bone.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  5. Number of Patients Achieving at Least 5% Loss of Body Weight in Any Post-Baseline Period

    Percentage loss of body weight = 100\*(postbaseline weight - baseline weight)/baseline weight

    Time frame: Visit 2 (Baseline) to Visit 7 (Week 16)

  6. Number of Participants Discontinuing the Trial by Visit (Week)

    The number of participants who discontinued by visit (non-cumulative).

    Time frame: Visit 2 (Baseline) to Visit 7 (Week 16)

  7. Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale

    Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  8. Mean Change From Baseline to 16 Week Endpoint in Blood Pressure

    Sitting blood pressure, taken from the same arm.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  9. Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)

    Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  10. Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose

    Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  11. Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin

    Patients should be fasting a minimum of eight hours prior to serum insulin measurement.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  12. Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  13. Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)

    HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  14. Number of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint

    Patient meets definition of metabolic syndrome if they have \>=3 risk factors: Waist circumference (men\>102cm, women\>88cm); triglycerides \>=1.7mmol/L; HDL cholesterol (men\<1.04mmol/L, women\<1.30mmol/L); blood pressure \>135/\>=85 mmHg; Fasting glucose \>=6.1mmol/L

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  15. Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale

    Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  16. Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale

    Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

  17. Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale

    Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning).

    Time frame: Visit 2 (Baseline) and Visit 7 (Week 16)

07

Results

Posted Jun 2, 2009

Participant flow

Participant flow — Overall Study
MilestoneSODOSOT
Started8465
Completed6550
Not completed1915
Withdrew: Adverse event22
Withdrew: Withdrawal by subject56
Withdrew: Lost to follow-up52
Withdrew: Protocol entry criteria not met22
Withdrew: Physician decision21
Withdrew: Noncompliance22
Withdrew: Protocol violation10

Outcome measures

PrimaryTime Course of Change From Baseline in Body Mass Index (BMI)

Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of changes at various time points throughout the study. Change = Time point value minus baseline (Visit 2) value.

Time frame:
Visit 2 (Baseline) to Visit 7 (16 Weeks)
Reported as:
Least squares mean · kilograms/square meters
Time Course of Change From Baseline in Body Mass Index (BMI)
kilograms/square metersSODOSOT
Week 2 (N=82, N=63)0.09 ± 0.060.16 ± 0.07
Week 4 (N=79, N=63)0.25 ± 0.080.27 ± 0.09
Week 8 (N=75, N=58)0.34 ± 0.120.32 ± 0.13
Week 12 (N=70, N=54)0.47 ± 0.160.54 ± 0.18
Week 16 (N=67, N=51)0.52 ± 0.180.72 ± 0.20
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.428 (P-value for Week 2 Change from Baseline. There was no adjustment for multiple comparisons.)
  • SODO vs SOT · Mixed Models Analysis · p = 0.859 (P-value for Week 4 Change from Baseline. There was no adjustment for multiple comparisons.)
  • SODO vs SOT · Mixed Models Analysis · p = 0.885 (P-value for Week 8 Change from Baseline. There was no adjustment for multiple comparisons.)
  • SODO vs SOT · Mixed Models Analysis · p = 0.784 (P-value for Week 12 Change from Baseline. There was no adjustment for multiple comparisons.)
  • SODO vs SOT · Mixed Models Analysis · p = 0.465 (P-value for Week 16 Change from Baseline. There was no adjustment for multiple comparisons)
SecondaryMean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)

Body mass index is an estimate of body fat based on body weight divided by height squared. Comparison of change from baseline to endpoint. Change = Endpoint (Week 16) minus Baseline (Week 0)

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · kilograms/square meters
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)
kilograms/square metersSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI)0.52 ± 1.490.67 ± 1.44
Statistical analysis
  • SODO vs SOT · ANCOVA · p = 0.442 · Least square mean change difference: -0.19 · 95% CI -0.67 to 0.30Change = Endpoint minus baseline
SecondaryMean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers

Body mass index is an estimate of body fat based on body weight divided by height squared. Comparisons of change from baseline to endpoint between participants who completed their treatment. Change = Endpoint value minus Baseline value.

Time frame:
Visit 2 (Baseline) and Visit 7 (16 Weeks)
Reported as:
Mean · kilograms/square meters
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers
kilograms/square metersSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Body Mass Index (BMI) for the Treatment Completers0.56 ± 1.590.79 ± 1.58
Statistical analysis
  • SODO vs SOT · ANCOVA · p = 0.328 · Least square mean change difference: -0.32 · 95% CI -0.95 to 0.32Change = Endpoint minus baseline
SecondaryMean Change From Baseline to 16 Week Endpoint in Weight

Weight of undressed patient (undergarments allowed), measured preferably at the same time each day.

Time frame:
Visit 2 (Baseline) and Visit 7 (16 Weeks)
Reported as:
Least squares mean · kilograms
Mean Change From Baseline to 16 Week Endpoint in Weight
kilogramsSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Weight1.42 ± 0.502.08 ± 0.57
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.385
SecondaryMean Change From Baseline to 16 Week Endpoint in Waist Circumference

Waist circumference is measured on a bare abodomen just above the hip bone.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · centimeters
Mean Change From Baseline to 16 Week Endpoint in Waist Circumference
centimetersSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Waist Circumference1.13 ± 5.250.77 ± 5.30
Statistical analysis
  • SODO vs SOT · ANCOVA · p = 0.914 · Least square mean change difference: 0.10 · 95% CI -1.65 to 1.84Change = endpoint minus baseline
SecondaryNumber of Patients Achieving at Least 5% Loss of Body Weight in Any Post-Baseline Period

Percentage loss of body weight = 100\*(postbaseline weight - baseline weight)/baseline weight

Time frame:
Visit 2 (Baseline) to Visit 7 (Week 16)
Reported as:
Number · participants
Number of Patients Achieving at Least 5% Loss of Body Weight in Any Post-Baseline Period
participantsSODOSOT
Up to Week 2 (N=82, N=63)00
Up to Week 4 (N=79, N=63)01
Up to Week 8 (N=75, N=58)22
Up to Week 12 (N=70, N=54)34
Up to Week 16 (N=67, N=51)46
Statistical analysis
  • SODO vs SOT · Fisher Exact · p = 0.325 (Up to Week 16 p-value)
SecondaryNumber of Participants Discontinuing the Trial by Visit (Week)

The number of participants who discontinued by visit (non-cumulative).

Time frame:
Visit 2 (Baseline) to Visit 7 (Week 16)
Reported as:
Number · participants
Number of Participants Discontinuing the Trial by Visit (Week)
participantsSODOSOT
Visit 3 (Week 2) Discontinuations31
Visit 4 (Week 4) Discontinuations31
Visit 5 (Week 8) Discontinuations56
Visit 6 (Week 12) Discontinuations56
Visit 7 (Week 16) Discontinuations31
SecondaryChange From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale

Participant chooses where they think their appetite lies on a 10 centimeter line between two anchors (0 - very poor appetite and 10 - very strong appetite). The possible range of scores is 0 to 100 and represents millimeters on the 10 centimeter line.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Least squares mean · units on a scale
Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale
units on a scaleSODOSOT
Change From Baseline to 16 Week Endpoint in Subjective Appetite Using a Visual Analog Scale-8.21 ± 2.26-5.02 ± 2.59
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.344
SecondaryMean Change From Baseline to 16 Week Endpoint in Blood Pressure

Sitting blood pressure, taken from the same arm.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · mm Hg
Mean Change From Baseline to 16 Week Endpoint in Blood Pressure
mm HgSODOSOT
Systolic Blood Pressure0.1 ± 11.62-0.1 ± 10.83
Diastolic Blood Pressure0.3 ± 7.550.8 ± 8.35
Statistical analysis
  • SODO vs SOT · Rank-Sum Test · p = 0.708 (Systolic Blood Pressure Change to Endpoint p-value)
  • SODO vs SOT · Rank-Sum Test · p = 0.453 (Diastolic Blood Pressure Change to Endpoint p-value)
SecondaryMean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)

Patients should be fasting a minimum of eight hours prior to lipoprotein measurements.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · millimole/Liter
Mean Change From Baseline to 16 Week Endpoint in Fasting Lipoproteins (Total Cholesterol, High-Density Lipoprotein Cholesterol [HDL-Cholesterol], Low-Density Lipoprotein Cholesterol [LDL-Cholesterol] [Calculated], and Triglycerides)
millimole/LiterSODOSOT
Total Cholesterol0.1 ± 0.740.2 ± 0.79
High-Density Lipoprotein Cholesterol-0.0 ± 0.24-0.0 ± 0.24
Low-Density Lipoprotein Cholesterol (N=73, N=57)0.1 ± 0.660.2 ± 0.53
Triglycerides0.1 ± 0.840.0 ± 1.01
Statistical analysis
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.187 (Total Cholesterol Change to Endpoint p-value)Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.163 (High-Density Lipoprotein Cholesterol Change to Endpoint p-value)Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.323 (Low-Density Lipoprotein Cholesterol Change to Endpoint p-value)Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.581 (Triglycerides Change to Endpoint p-value)Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
SecondaryChange From Baseline to 16 Week Endpoint in Fasting Plasma Glucose

Patients should be fasting a minimum of eight hours prior to plasma glucose measurement.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · millimole/Liter
Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose
millimole/LiterSODOSOT
Change From Baseline to 16 Week Endpoint in Fasting Plasma Glucose0.2 ± 0.790.1 ± 0.48
Statistical analysis
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.227Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
SecondaryMean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin

Patients should be fasting a minimum of eight hours prior to serum insulin measurement.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · microIU/milliliter
Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin
microIU/milliliterSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Fasting Serum Insulin2.4 ± 17.72-0.1 ± 5.52
Statistical analysis
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.020Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
SecondaryMean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin
Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · percent
Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin
percentSODOSOT
Mean Change From Baseline to 16 Week Endpoint in Glycosylated Hemoglobin0.0 ± 0.240.0 ± 0.28
Statistical analysis
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.834Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals of this regression in CMH test.
SecondaryMean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)

HOMA-S is an estimate of insulin sensitivity. The HOMA model is a computer model of the glucose insulin feedback system in the fasted state. The model consists of a number of non-linear empirical equations describing the functions of organs and tissues involved in glucose regulation.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Mean · percent sensitivity
Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)
percent sensitivitySODOSOT
Mean Changes From Baseline to 16 Week Endpoint Homeostasis Model Assessments of Insulin Sensitivity HOMA-S (Calculated)-18.5 ± 58.91-9.8 ± 62.61
Statistical analysis
  • SODO vs SOT · Cochran-Mantel-Haenszel · p = 0.022Ranks of change from baseline were regressed on ranks of baseline value of assay. Treatments compared using residuals on this regression in CMH test.
SecondaryNumber of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint

Patient meets definition of metabolic syndrome if they have \>=3 risk factors: Waist circumference (men\>102cm, women\>88cm); triglycerides \>=1.7mmol/L; HDL cholesterol (men\<1.04mmol/L, women\<1.30mmol/L); blood pressure \>135/\>=85 mmHg; Fasting glucose \>=6.1mmol/L

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Number · participants
Number of Participants Meeting a Definition for the Presence of Metabolic Syndrome as Defined by Adult Treatment Panel III (ATP III) Criteria at Baseline and 16 Week Endpoint
participantsSODOSOT
Baseline - Metabolic Syndrome (N=82, N=65)1816
Endpoint - Metabolic Syndrome (N=70, N=52)1810
Statistical analysis
  • SODO vs SOT · Fisher Exact · p = 0.515 (Endpoint Metabolic Syndrome p-value)
SecondaryMean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale

Measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale
units on a scaleSODOSOT
Mean Change From Baseline to 16 Week Endpoint in the Clinical Global Impression-Severity (CGI-S) Scale-0.26 ± 0.07-0.09 ± 0.08
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.118
SecondaryMean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale

Measures subjective well-being for previous 7 days. 20 items covering 5 health domains (subscales) (4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Subscale scores range from 1 to 24. Total score ranges from 1 to 120.

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale
units on a scaleSODOSOT
Mean Change From Baseline to 16 Week Endpoint in the Subjective Well-Being Under Neuroleptics (SWN) Scale4.79 ± 1.521.60 ± 1.73
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.161
SecondaryMean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale

Measures physician's judgment of a patient's overall level of functioning. Ratings are based on a scale of 1 to 100, with the following classification range: 1-10 (severely impaired) to 91-100 (superior functioning).

Time frame:
Visit 2 (Baseline) and Visit 7 (Week 16)
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale
units on a scaleSODOSOT
Mean Change From Baseline to 16 Week Endpoint in the Global Assessment of Functioning (GAF) Scale4.61 ± 1.052.72 ± 1.20
Statistical analysis
  • SODO vs SOT · Mixed Models Analysis · p = 0.229

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SODO———
SOT———
Most frequent serious events
Most frequent serious events
EventSODOSOT
DizzinessNervous system disorders1/840/65
Suicide attemptPsychiatric disorders1/840/65
Most frequent other events
Showing 10 of 61
Most frequent other events
EventSODOSOT
Increased appetiteMetabolism and nutrition disorders9/8410/65
FatigueGeneral disorders3/845/65
HeadacheNervous system disorders5/845/65
SomnolenceNervous system disorders5/845/65
DizzinessNervous system disorders0/844/65
NasopharyngitisInfections and infestations1/843/65
InsomniaPsychiatric disorders2/843/65
ConstipationGastrointestinal disorders3/841/65
Decreased appetiteMetabolism and nutrition disorders3/840/65
AnxietyPsychiatric disorders3/842/65

Baseline characteristics

Age Continuous
Age Continuous(years)SODOSOTTotal
Mean38.6 ± 13.1338.7 ± 12.2338.6 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)SODOSOTTotal
Female363268
Male483381
Region of Enrollment
Region of Enrollment(participants)SODOSOTTotal
United States231841
Mexico272350
Canada292150
Netherlands538
Presence of Metabolic Syndrome
Presence of Metabolic Syndrome(participants)SODOSOTTotal
No6449113
Yes181634
Unknown202
Psychiatric Illness
Psychiatric Illness(participants)SODOSOTTotal
Schizophrenia463682
Schizophreniform729
Schizoaffective disorder31215
Other related psychiatric disorder112
Bipolar disorder271441
Race/Ethnicity
Race/Ethnicity(participants)SODOSOTTotal
African Descent11415
Caucasian423678
East/Southeast Asian213
First Nations202
Hispanic272350
Other011
Blood Pressure
Blood Pressure(mm Hg)SODOSOTTotal
Systolic Blood Pressure120.3 ± 16.45119.0 ± 12.49119.7 ± 14.82
Diastolic Blood Pressure77.6 ± 9.6275.8 ± 9.1576.8 ± 9.43
Body Mass Index
Body Mass Index(kilograms/meters-squared)SODOSOTTotal
Mean28.0 ± 5.6328.3 ± 4.7628.1 ± 5.26

11 further baseline measures are reported on the registry.

08

Study locations

21 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Escondido, California 92025, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden Grove, California 92845, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    National City, California 91950, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orange, California 92868, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Atlanta, Georgia 30308, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Las Vegas, Nevada 89102, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Staten Island, New York 10312, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Penticton, British Columbia V2A 4M4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3E 3N4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dartmouth, Nova Scotia B2Y 3Z9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, Nova Scotia B3H 2E2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sydney, Nova Scotia B1S 2E8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chatham, Ontario N7L 1B7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kingston, Ontario K7L 4X3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sudbury, Ontario P3C 1T4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Windsor, Ontario N9C 3Z4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, Quebec J1G 1W4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 01030, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Amersfoort, 3816 CP, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rotterdam, 3015 GD, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00918, Puerto Rico
09

References and documents

Publications

  • Case M, Treuer T, Karagianis J, Hoffmann VP. The potential role of appetite in predicting weight changes during treatment with olanzapine. BMC Psychiatry. 2010 Sep 14;10:72. doi: 10.1186/1471-244X-10-72. PubMed 20840778 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2006, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2006
First posted
Mar 17, 2006
Start
Mar 2006
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jun 2, 2009
Last update
Jun 10, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00303602
First posted
Mar 17, 2006
Start date
Mar 2006
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jun 2, 2009
Last update
Jun 10, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion